Detailed Abstract
[BP Oral Presentation 2 - Biliary & Pancreas (Biliary Disease/Surgery)]
[BP OP 2-S6] The Combination Therapy with Gemcitabine And Cisplatin Plus S-1 And Subsequent Conversion Surgery Improves Prognosis of Initially Unresectable Upper Biliary Tract Cancers
Hisashi KOSAKA 1, Kosuke MATSUI 1, Morihiko ISHIZAKI 1, Hideyuki MATSUSHIMA 1, Hidekazu YAMAMOTO 1, Masaki KAIBORI 1
1 Surgery, Kansai Medical University, JAPAN
Background : For the past decade, few options have been available for chemotherapy for unresectable biliary tract cancers (UR-BTC). Combination therapy with gemcitabine and cisplatin plus S-1 (GCS) was newly identified as an additional option in Japan. We retrospectively analyzed the clinical results of GCS therapy and subsequent conversion surgery (CS).
Methods : The clinical data of 60 consecutive patients who received GCS therapy for UR-BTC at our university hospital during the past 5 years were analyzed.
Results : All patients received GCS therapy as first-line chemotherapy; the response rate was 33.9%, and subsequent CS was performed in 35.0%. 81.0 percent of patients who underwent CS required more than bisectionectomy of the liver with extrahepatic bile duct resection. The median overall survival (OS) of patients who received GCS therapy and subsequent CS was significantly longer than the median OS of patients who received GCS therapy alone (CS, 28.0 months vs GCS, 12.4 months; p <0.001). A multivariate logistic regression analysis revealed that potential candidates for CS are those with unresectable hilar cholangiocarcinoma or intrahepatic cholangiocarcinoma with ALBI grade 1.
Conclusions : GCS therapy and subsequent CS may contribute for long-term survive in patients with unresectable upper biliary tract cancers.
Methods : The clinical data of 60 consecutive patients who received GCS therapy for UR-BTC at our university hospital during the past 5 years were analyzed.
Results : All patients received GCS therapy as first-line chemotherapy; the response rate was 33.9%, and subsequent CS was performed in 35.0%. 81.0 percent of patients who underwent CS required more than bisectionectomy of the liver with extrahepatic bile duct resection. The median overall survival (OS) of patients who received GCS therapy and subsequent CS was significantly longer than the median OS of patients who received GCS therapy alone (CS, 28.0 months vs GCS, 12.4 months; p <0.001). A multivariate logistic regression analysis revealed that potential candidates for CS are those with unresectable hilar cholangiocarcinoma or intrahepatic cholangiocarcinoma with ALBI grade 1.
Conclusions : GCS therapy and subsequent CS may contribute for long-term survive in patients with unresectable upper biliary tract cancers.
SESSION
BP Oral Presentation 2
Room C 3/22/2024 4:30 PM - 5:30 PM